CompoSecure, L.L.C. is a design and manufacturing company founded in 2000, specializing in premium financial cards. The firm produces a range of EMV chip and contactless metal cards, including full metal, metal hybrid, metal veneer, and embedded metal options. Additionally, CompoSecure offers customized metal card manufacturing services and patented pre-laminated products, catering to plastic card manufacturers. The company also creates high-security identification cards for clients in various sectors, including financial services, luxury retail, secure identification, and hospitality. With a management team that boasts over 200 years of combined experience in the card industry, CompoSecure is recognized for its innovative design capabilities and commitment to addressing high-security requirements for both public and private sector clients. Headquartered in Somerset, New Jersey, the company serves a diverse clientele, including luxury resorts, casinos, and government agencies, both domestically and internationally.
Urgent.ly’s Roadside is a digital roadside assistance platform that features a roadside assistance industry to the benefit of global brands, roadside assistance professionals, and consumers. Its solution delivers the quickest, safest, and most innovative roadside assistance service, products and technology by combining location-based services, real-time data, AI, and machine-to-machine communication.
BigBear.ai is a decision dominance serving the national defense and intelligence communities. The Company delivers high-end capabilities across the data and digital spectrum to deliver information superiority and decision support. BigBear.ai provides a comprehensive suite of solutions including artificial intelligence and machine learning, data science, advanced analytics, offensive and defensive cyber, data management, cloud solutions, digital engineering, and systems integration.
Lime is a company focused on providing sustainable transportation solutions to address the first and last mile mobility challenges in urban areas. It offers an array of smart mobility options, including electric scooters and bikes, designed to be affordable and convenient for users while minimizing their carbon footprint. Lime collaborates with cities to deploy its fleet, which features electric kick-scooters and bikes equipped with GPS and self-activating locks, ensuring reliable access for riders. Through its services, Lime aims to encourage a shift in transportation behavior, promoting a greener future for urban mobility.
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company that develops and commercializes innovative medicines for rare neuromuscular and pulmonary diseases, addressing high unmet medical needs. The company focuses on a product portfolio for Duchenne muscular dystrophy (DMD), including late-stage candidates such as Puldysa (idebenone) and vamorolone, which aim to treat patients regardless of their specific mutations, disease stage, or age. Additionally, Santhera's clinical pipeline includes lonodelestat (POL6014) for cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil and an exploratory gene therapy for congenital muscular dystrophies. The company also out-licenses the rights to its approved product Raxone (idebenone) for Leber's hereditary optic neuropathy outside North America and has collaborated with Cold Spring Harbor Laboratory to explore lonodelestat as a potential treatment for COVID-19-related acute respiratory distress syndrome. Headquartered in Pratteln, Switzerland, Santhera primarily generates its revenue from the European Union.
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company that develops and commercializes innovative medicines for rare neuromuscular and pulmonary diseases, addressing high unmet medical needs. The company focuses on a product portfolio for Duchenne muscular dystrophy (DMD), including late-stage candidates such as Puldysa (idebenone) and vamorolone, which aim to treat patients regardless of their specific mutations, disease stage, or age. Additionally, Santhera's clinical pipeline includes lonodelestat (POL6014) for cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil and an exploratory gene therapy for congenital muscular dystrophies. The company also out-licenses the rights to its approved product Raxone (idebenone) for Leber's hereditary optic neuropathy outside North America and has collaborated with Cold Spring Harbor Laboratory to explore lonodelestat as a potential treatment for COVID-19-related acute respiratory distress syndrome. Headquartered in Pratteln, Switzerland, Santhera primarily generates its revenue from the European Union.
Quotient Biodiagnostics specializes in the development and provision of high-quality immunohematology products for hospitals and blood banks in the United States. The company leverages over 30 years of expertise in research, development, and manufacturing through its wholly-owned subsidiary, Alba Bioscience. Quotient offers a range of transfusion diagnostics products that have been distributed globally, either directly or through partnerships with major transfusion companies. By focusing on the needs of healthcare institutions, Quotient aims to enhance the quality and reliability of blood transfusion practices.
Gamida Cell Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for blood cancers and serious blood diseases. The company's lead product candidate, omidubicel, utilizes expanded hematopoietic stem cells and differentiated immune cells, and is currently undergoing Phase 3 trials for high-risk hematologic malignancies, alongside Phase 1/2 trials for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy, which is in Phase 1/2 studies for relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, the company leverages a proprietary expansion platform that enhances the therapeutic potential of umbilical cord blood-derived cells and natural killer cells, aiming to address significant unmet clinical needs in the field of regenerative medicine.
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company that develops and commercializes innovative medicines for rare neuromuscular and pulmonary diseases, addressing high unmet medical needs. The company focuses on a product portfolio for Duchenne muscular dystrophy (DMD), including late-stage candidates such as Puldysa (idebenone) and vamorolone, which aim to treat patients regardless of their specific mutations, disease stage, or age. Additionally, Santhera's clinical pipeline includes lonodelestat (POL6014) for cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil and an exploratory gene therapy for congenital muscular dystrophies. The company also out-licenses the rights to its approved product Raxone (idebenone) for Leber's hereditary optic neuropathy outside North America and has collaborated with Cold Spring Harbor Laboratory to explore lonodelestat as a potential treatment for COVID-19-related acute respiratory distress syndrome. Headquartered in Pratteln, Switzerland, Santhera primarily generates its revenue from the European Union.
Protalix Biotherapeutics is a biopharmaceutical company based in Karmiel, Israel, that specializes in the development and commercialization of recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based protein expression system. The company is primarily known for its product Elelyso, a recombinant glucocerebrosidase enzyme approved for the treatment of Gaucher disease. Protalix is advancing a diverse pipeline, including PRX-102, which is in phase III clinical trials for Fabry disease, and OPRX-106, a therapeutic candidate for inflammatory bowel disease that has completed phase IIa trials for ulcerative colitis. Additionally, PRX-110, aimed at treating cystic fibrosis, and PRX-115, a treatment for gout, are also in development. Protalix has established partnerships with leading pharmaceutical companies, including Pfizer, and has a commercial presence in Brazil and other regions of Latin America. The company aims to target significant pharmaceutical markets with its innovative therapies for genetic and inflammatory disorders.
Inseego Corp. specializes in designing and developing mobile, Internet of Things (IoT), and cloud solutions for a diverse range of customers, including large enterprises, service providers, and small to medium-sized businesses globally. The company offers a variety of wireless hardware products, including 3G, 4G, and 5G devices tailored for vertical markets such as private LTE/5G networks, telematics, remote monitoring, and fixed wireless access. Its product lineup includes fixed wireless routers, mobile hotspots, integrated telematics, and USB modems, all supported by software applications and cloud services that facilitate data analysis and remote hardware management. Inseego also provides software-as-a-service (SaaS) solutions under the Ctrack brand, covering fleet management, asset tracking, and usage-based insurance. Headquartered in San Diego, California, Inseego was established in 1996 and has a significant revenue base in the United States and Canada.
Emergent Payments, Inc. specializes in providing payment solutions for merchants operating in high-growth markets such as Latin America, Asia, India, and Eastern Europe. The company’s Pay+ platform supports various payment methods, including international cards, bank transfers, local cards, wallets, and mobile payments. Additionally, it offers risk management, tax compliance solutions, and tailored implementation services that include technical support and fraud monitoring. Emergent Payments serves a diverse range of clients, particularly in the digital entertainment, software, and educational publishing sectors. Founded in 2007 and headquartered in Palo Alto, California, the company has development centers in North Carolina and Shanghai, along with international offices in several countries, including Luxembourg, India, and Japan. Emergent Payments rebranded from Live Gamer in 2015 to concentrate on its core payment technology, enhancing its capabilities in emerging markets.
Private Equity Round in 2007
ACE*COMM Corporation provided operations support systems (OSS) and mobile applications for telecommunications service providers and enterprises. Its OSS solutions were applicable to various networks that include wired, wireless, voice, data, multimedia, and Internet communications networks. ACE*COMM marketed and sold its solutions in the United States, Canada, Latin America, Europe, the Middle East, Africa, and the Asia Pacific. It had strategic alliances with telecommunication and Internet equipment manufacturers, computer equipment manufacturers, and telecom systems integrators. The company was founded in 1983 and was headquartered in Gaithersburg, Maryland.
EUSA Pharma, established in March 2015 and headquartered in the UK, is a specialty pharmaceutical company with a global presence, particularly in Europe and the USA. The company specializes in oncology and critical diseases, offering a portfolio of five approved specialty hospital products, including Caphosol®, Xenazine®, Collatamp®, Custodiol®, and Fomepizole®. EUSA Pharma focuses on addressing rare diseases and conditions like oral mucositis, a debilitating side effect of cancer treatments, with effective biopharmaceutical solutions. The firm submitted a marketing authorization application for FOTIVDA (tivozanib HCL) as a first-line therapy for renal cell carcinoma in early 2016. EUSA Pharma aims to expand its product offerings through acquisitions and in-licensing, supported by significant funding from prominent life science investors. With direct commercial operations and a distribution network that spans approximately 40 countries, EUSA Pharma is well-positioned to meet the needs of patients worldwide.
EUSA Pharma, established in March 2015 and headquartered in the UK, is a specialty pharmaceutical company with a global presence, particularly in Europe and the USA. The company specializes in oncology and critical diseases, offering a portfolio of five approved specialty hospital products, including Caphosol®, Xenazine®, Collatamp®, Custodiol®, and Fomepizole®. EUSA Pharma focuses on addressing rare diseases and conditions like oral mucositis, a debilitating side effect of cancer treatments, with effective biopharmaceutical solutions. The firm submitted a marketing authorization application for FOTIVDA (tivozanib HCL) as a first-line therapy for renal cell carcinoma in early 2016. EUSA Pharma aims to expand its product offerings through acquisitions and in-licensing, supported by significant funding from prominent life science investors. With direct commercial operations and a distribution network that spans approximately 40 countries, EUSA Pharma is well-positioned to meet the needs of patients worldwide.
BravoSolution SpA specializes in supply management technology software and services tailored for procurement and sourcing applications. The company provides a comprehensive suite of solutions that includes spend analysis to enhance savings and compliance, eSourcing for collaborative sourcing efforts, supplier performance management, and contract management to streamline contract processes. Additionally, BravoSolution offers cloud-based tools such as BravoAlign for procurement alignment and transformation, and BravoAdvantage, which supports organizations in generating procurement initiatives from demand to contract. Their analytics platform, BravoAdvantage Analytics, allows procurement professionals to visualize data and create intuitive reports for stakeholders. BravoSolution also delivers collaboration services across various sectors, including transportation and temporary labor, as well as government solutions focused on spend visibility and electronic sourcing. Founded in 2000 and headquartered in Milan, Italy, BravoSolution operates additional offices globally and is a subsidiary of JAGGAER, Inc.
Pharmacopeia, Inc. is a biopharmaceutical company focused on the discovery and development of therapeutics to meet critical medical needs. The company's internal program portfolio includes PS433540, a dual-acting angiotensin and endothelin receptor antagonist currently undergoing phase II clinical development for cardiovascular and renal diseases, such as hypertension and diabetic nephropathy. Another candidate, PS178990, is a muscle-selective SARM agonist in phase I clinical development. Additionally, Pharmacopeia is advancing PS031291, a preclinical product aimed at treating multiple myeloma and inflammatory diseases like rheumatoid arthritis, along with JAK3 inhibitors targeting dermatologic and ocular conditions, including psoriasis and dry eye. Founded in 1993 and based in Cranbury, New Jersey, Pharmacopeia has formed strategic alliances with major pharmaceutical companies such as Bristol-Myers Squibb and GlaxoSmithKline. It became a subsidiary of Ligand Pharmaceuticals Inc. in 2008.
Private Equity Round in 2005
Lexar is a well-established global brand specializing in memory solutions, with over 20 years of experience in the industry. The company offers a diverse range of products, including memory cards, USB flash drives, card readers, and solid-state drives, catering to markets such as gaming, professional photography, and personal data storage. Lexar emphasizes quality and reliability, conducting extensive testing on its products in specialized labs equipped with over 1,100 digital devices to ensure optimal performance and compatibility. Lexar's products are widely available through major retail and online stores around the world. For further information and support, consumers can visit the company's official website.
Strategic Data Corp. is an interactive technology company focused on optimizing the delivery of online advertising. Founded in 1999, SDC has specialized in developing display ad serving and yield-optimization technology that significantly increases the revenue for its clients. Currently, it operates as a subsidiary of Fox Interactive Media.